Computationally designed antibody-drug conjugates self-assembled via affinity ligands.


Journal

Nature biomedical engineering
ISSN: 2157-846X
Titre abrégé: Nat Biomed Eng
Pays: England
ID NLM: 101696896

Informations de publication

Date de publication:
11 2019
Historique:
received: 10 10 2018
accepted: 22 09 2019
pubmed: 7 11 2019
medline: 10 3 2020
entrez: 6 11 2019
Statut: ppublish

Résumé

Antibody-drug conjugates (ADCs) combine the high specificity of antibodies with cytotoxic payloads. However, the present strategies for the synthesis of ADCs either yield unstable or heterogeneous products or involve complex processes. Here, we report a computational approach that leverages molecular docking and molecular dynamics simulations to design ADCs that self-assemble through the non-covalent binding of the antibody to a payload that we designed to act as an affinity ligand for specific conserved amino acid residues in the antibody. This method does not require modifications to the antibody structure and yields homogenous ADCs that form in less than 8 min. We show that two conjugates, which consist of hydrophilic and hydrophobic payloads conjugated to two different antibodies, retain the structure and binding properties of the antibody and its biological specificity, are stable in plasma and improve anti-tumour efficacy in mice with non-small cell lung tumour xenografts. The relative simplicity of the approach may facilitate the production of ADCs for the targeted delivery of cytotoxic payloads.

Identifiants

pubmed: 31686001
doi: 10.1038/s41551-019-0470-8
pii: 10.1038/s41551-019-0470-8
doi:

Substances chimiques

Antibodies 0
Antineoplastic Agents 0
Cytotoxins 0
Immunoconjugates 0
Ligands 0
Trastuzumab P188ANX8CK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

917-929

Commentaires et corrections

Type : ErratumIn

Auteurs

Nimish Gupta (N)

Akamara Therapeutics, Cambridge, MA, USA. nimishgupta@gmail.com.
Akamara Biomedicine Private Limited, Delhi, India. nimishgupta@gmail.com.
India Innovation Research Center, Delhi, India. nimishgupta@gmail.com.
Symbiosis International (Deemed University), Pune, India. nimishgupta@gmail.com.

Aasif Ansari (A)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Gaurao V Dhoke (GV)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Maheshwerreddy Chilamari (M)

Indian Institute of Science Education and Research Bhopal, Bhopal, India.

Jwala Sivaccumar (J)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Smita Kumari (S)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Snigdha Chatterjee (S)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Ravinder Goyal (R)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Pradip Kumar Dutta (PK)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Mallik Samarla (M)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Madhumita Mukherjee (M)

Indian Institute of Science Education and Research Bhopal, Bhopal, India.

Arindam Sarkar (A)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.
India Innovation Research Center, Delhi, India.

Swadhin K Mandal (SK)

Indian Institute of Science Education and Research Kolkata, Mohanpur, India.

Vishal Rai (V)

Indian Institute of Science Education and Research Bhopal, Bhopal, India.

Goutam Biswas (G)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Aniruddha Sengupta (A)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.
India Innovation Research Center, Delhi, India.

Sudip Roy (S)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.

Monideepa Roy (M)

Akamara Therapeutics, Cambridge, MA, USA.
Akamara Biomedicine Private Limited, Delhi, India.
India Innovation Research Center, Delhi, India.
Symbiosis International (Deemed University), Pune, India.

Shiladitya Sengupta (S)

Center for Engineered Therapeutics, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA. ssengupta2@bwh.harvard.edu.
Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. ssengupta2@bwh.harvard.edu.
Dana-Farber Cancer Institute, Boston, MA, USA. ssengupta2@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria

Classifications MeSH